Amgen, Eli Lilly, Viking Therapeutics Shares Rise Pre-Bell After Novo Nordisk's Obesity Treatment Falls Short of Expectations

MT Newswires Live

2024/12/20

Amgen (AMGN), Eli Lilly (LLY) and Viking Therapeutics (VKTX) shares advanced 3.7%, 6.4% and 9.2%, respectively premarket Friday after Novo Nordisk's (NVO) CagriSema experimental obesity therapy fell short of expectations despite meeting the primary endpoint in a phase 3 trial.

Novo Nordisk said that at 68 weeks, those on CagriSema experienced a weight loss of 22.7%, lower than the company's expected 25%. The company's shares slipped 21% pre-bell.

Novo Nordisk's announcement comes a day after the US Food and Drug Administration said that Eli Lilly's tirzepatide injection products Zepbound and Mounjaro are no longer in shortage.

Amgen (AMGN) and Viking Therapeutics (VKTX) are separately developing their own obesity drugs.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2492497704"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492497704\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2492497704?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 22:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492497704","market":"hk","top_or_hot":-1,"title":"Amgen, Eli Lilly, Viking Therapeutics Shares Rise Pre-Bell After Novo Nordisk's Obesity Treatment Falls Short of Expectations","media":"MT Newswires Live","content":"<html><body><p> Amgen (AMGN), Eli Lilly (LLY) and Viking <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VKTX) shares advanced 3.7%, 6.4% and 9.2%, respectively premarket Friday after Novo Nordisk's (NVO) CagriSema experimental obesity therapy fell short of expectations despite meeting the primary endpoint in a phase 3 trial.</p><p>Novo Nordisk said that at 68 weeks, those on CagriSema experienced a weight loss of 22.7%, lower than the company's expected 25%. The company's shares slipped 21% pre-bell.</p><p>Novo Nordisk's announcement comes a day after the US Food and Drug Administration said that Eli Lilly's tirzepatide injection products Zepbound and Mounjaro are no longer in shortage.</p><p>Amgen (AMGN) and Viking Therapeutics (VKTX) are separately developing their own obesity drugs.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amgen, Eli Lilly, Viking Therapeutics Shares Rise Pre-Bell After Novo Nordisk's Obesity Treatment Falls Short of Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmgen, Eli Lilly, Viking Therapeutics Shares Rise Pre-Bell After Novo Nordisk's Obesity Treatment Falls Short of Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-20 22:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Amgen (AMGN), Eli Lilly (LLY) and Viking <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VKTX) shares advanced 3.7%, 6.4% and 9.2%, respectively premarket Friday after Novo Nordisk's (NVO) CagriSema experimental obesity therapy fell short of expectations despite meeting the primary endpoint in a phase 3 trial.</p><p>Novo Nordisk said that at 68 weeks, those on CagriSema experienced a weight loss of 22.7%, lower than the company's expected 25%. The company's shares slipped 21% pre-bell.</p><p>Novo Nordisk's announcement comes a day after the US Food and Drug Administration said that Eli Lilly's tirzepatide injection products Zepbound and Mounjaro are no longer in shortage.</p><p>Amgen (AMGN) and Viking Therapeutics (VKTX) are separately developing their own obesity drugs.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0456855351.SGD","symbol_name":"JPMorgan Funds - Global Equity A (acc) SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492497704","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492497704","pubTimestamp":1734704522,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amgen , Eli Lilly  and Viking Therapeutics  shares advanced 3.7%, 6.4% and 9.2%, respectively premarket Friday after Novo Nordisk's  CagriSema experimental obesity therapy fell short of expectations despite meeting the primary endpoint in a phase 3 trial.Novo Nordisk said that at 68 weeks, those on CagriSema experienced a weight loss of 22.7%, lower than the company's expected 25%. The company's shares slipped 21% pre-bell.Novo Nordisk's announcement comes a day after the US Food and Drug Administration said that Eli Lilly's tirzepatide injection products Zepbound and Mounjaro are no longer in shortage.Amgen  and Viking Therapeutics  are separately developing their own obesity drugs.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","BK4588":"碎股","AMGN":"安进","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LLY":"礼来","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4532":"文艺复兴科技持仓","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","NVO":"诺和诺德","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","BK7104":"黄金","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","NVO.AU":"NOVO RESOURCES CORP-CDI","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","VKTX":"Viking Therapeutics, Inc.","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC"},"translate_title":"诺和诺德肥胖治疗未达预期后，安进、礼来、Viking Therapeutics股价上涨盘前","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO.AU":1,"VKTX":1,"AMGN":1,"LLY":1,"NVO":1},"content_text":"Amgen (AMGN), Eli Lilly (LLY) and Viking Therapeutics (VKTX) shares advanced 3.7%, 6.4% and 9.2%, respectively premarket Friday after Novo Nordisk's (NVO) CagriSema experimental obesity therapy fell short of expectations despite meeting the primary endpoint in a phase 3 trial.Novo Nordisk said that at 68 weeks, those on CagriSema experienced a weight loss of 22.7%, lower than the company's expected 25%. The company's shares slipped 21% pre-bell.Novo Nordisk's announcement comes a day after the US Food and Drug Administration said that Eli Lilly's tirzepatide injection products Zepbound and Mounjaro are no longer in shortage.Amgen (AMGN) and Viking Therapeutics (VKTX) are separately developing their own obesity drugs.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}